Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;28(3):291-299.
doi: 10.1007/s40291-024-00699-w. Epub 2024 Mar 6.

Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes

Hanh Nguyen  1   2   3 , Kathryn Hird  4 , Joe Cardaci  4   5 , Steven Smith  5 , Nat P Lenzo  4   5
Affiliations

Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes

Hanh Nguyen et al. Mol Diagn Ther. 2024 May.

Abstract

Introduction: Whilst prostate cancer is the fourth most common cancer globally, effective therapies for patients with advanced disease are lacking. In recent years, interest in using theranostic agents to treat castrate-resistant prostate cancer (CRPC) and metastatic prostate cancer has emerged. Lu-TLX591 monoclonal antibody is a potential agent of significance; however, to date, reports on its toxicity and efficacy have been limited to small clinical trials in heavily pretreated patients. This retrospective study describes the real-world toxicity and efficacy profile of Lu-TLX591.

Methods: Eighteen patients received Lu-TLX591 at two private oncology centres in Australia. Patients were eligible if they had CRPC or metastatic prostate cancer and prostate-specific membrane antigen (PSMA)-avid disease confirmed by PSMA-positron emission tomography (PET). Patients received two cycles of Lu-TLX591 monoclonal antibody (177 Lu-DOTA-rosopatamab) each dosed from 1.01-2.85 GBq, 14 days apart. Patient side effects, blood test results and radiology reports were recorded on the patient's electronic medical record (eMR).

Results: Prominent side effects included fatigue (55.6%), anorexia (16.7%), nausea (11.1%), and transfusion reactions (11.1%). All-grade haematological toxicities included lymphopenia (61.1%), anaemia (22.2%), leukopenia (27.8%), neutropenia (27.8%), and thrombocytopenia (27.8%). Grade 4 toxicity included lymphopenia (6.7%) and thrombocytopenia (6.7%). Patients' prostate-specific antigen (PSA) responses were as follows; ≥ 30% PSA decline (27.8%), ≥ 50% PSA decline (11.4%) and any PSA decline (38.9%). Follow-up radiology revealed 54.5% stable disease, 45.4% disease progression and 9.1% disease regression.

Conclusion: Lu-TLX591 was safely administered at acceptable toxicity and its efficacy reflects previous clinical trials. Larger studies are required and are underway (NCT04786847; NCT05146973; NCT04876651) to determine Lu-TLX591 effectiveness amongst different prostate cancer populations and compare its efficacy against peptide-based radiopharmaceutical agents.

PubMed Disclaimer

Conflict of interest statement

NL is a scientific advisor to Telix Pharmaceuticals and a principal investigator on the ProstACT trials using Lu-TLX591. No other authors (KH, JC, SS and HN) have relevant financial or non-financial interests to declare.

Figures

Figure 1:
Figure 1:
Rates of Grade 0–4 haematologic toxicity as defined by the CTCAE V5
See this image and copyright information in PMC

References

    1. American Society of Clinical Oncology (ASCO). Prostate Cancer: Statistics. https://www.cancer.net/cancer-types/prostate-cancer/statistics. Accessed 6 Apr 2023.
    1. Sharma R. The burden of prostate cancer is associated with human development index: evidence from 87 countries, 1990–2016. EPMA J. 2019;10(2):137–152. doi: 10.1007/s13167-019-00169-y. - DOI - PMC - PubMed
    1. Seifert R, Alberts IL, Afshar-Oromieh A, Rahbar K. Prostate cancer theranostics: PSMA targeted therapy. PET Clin. 2021;16(3):391–396. doi: 10.1016/j.cpet.2021.03.004. - DOI - PubMed
    1. O'Dwyer E, Bodei L, Morris MJ. The role of theranostics in prostate cancer. Sem Radiat Oncol. 2021;31(1):71–82. doi: 10.1016/j.semradonc.2020.07.004. - DOI - PMC - PubMed
    1. Harris AE, Metzler VM, Lothion-Roy J, et al. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Review. Front Endocrinol. 2022 doi: 10.3389/fendo.2022.1006101. - DOI - PMC - PubMed

Publication types

MeSH terms